NVIDIA Co. NASDAQ: NVDA Artificial Intelligence (AI) is the undisputed leader of the revolution. The company envisioned an AI future 12 years ago and began implementing the blueprint to dominate. With such proven vision and execution, investors take notice when NVIDIA sees an opportunity and invests their money in promising AI companies.
There are 2 stocks Computer and technology field NVIDIA has made investments that can prove compelling for your portfolio.
Recursion Pharmaceuticals: An AI-Powered Drug Discovery Powerhouse
Bringing a drug to market from drug discovery to US FDA approval can take more than 15 years at a cost of $2.5 billion. The initial daunting task of drug discovery can take months to over a year to complete. Up to 90% of all drug candidates fail in clinical trials after spending millions of dollars.
Recursion Pharmaceuticals Inc. NASDAQ: RXRX Accelerates the drug discovery process by using AI, automated biology and high-throughput screening and machine learning algorithms to identify and predict the efficacy of potential drug targets. NVIDIA has invested $50 million in Recursion to help accelerate the development of its AI drug discovery models.
Recursion Data Universe enables millions of weekly wet lab experiments
Recursion Pharmaceuticals Today
(as of 12/4/2024 06:15 PM ET)
- 52-week range
- $5.60
▼
$15.74
- Price target
- $9.25
Recursion’s massive proprietary chemical and biological database, called Recursion’s Data Universe, spans more than 23 petabytes, including data on proteins, genes and pathways associated with disease. Its recursion map is made up of hundreds of billions of discoverable chemical and biological hypotheses enabling millions of wet lab experiments weekly.
Iteration can assess potential drug failure much earlier in the process, save millions of dollars and bring drugs to market faster and more efficiently. Recursion has a partnership with Bayer and Roche Holding AG OTCMKTS: RHHBY.
Recurson has five treatments in clinical trials and is expected to increase that number to 10 with the $688 million acquisition of Rival. Excitea Plc NASDAQ: EXAI. In partnership with Exscientia Sanofi Nasdaq: SNY and Merck KGAA of Germany. New investors in Recursion stock will get both companies for the price of one. The merger is an all-stock transaction.
Najat Khan, Chief R&D Officer, Recursion Pharmaceuticals commented, “The coming together of Recursion and Exciencia is exceptionally complementary in terms of end-to-end applications in research all the way from biology to chemistry. It enables you to make drugs better and faster, and that’s what we’re trying to do.”
Serve Robotics: Delivering Takeout to a Neighborhood Near You
Service Robotics today
(as of 12/4/2024 06:15 PM ET)
- 52-week range
- $1.77
▼
$24.09
- Price target
- $16.00
Food delivery is moving from people to robots. Serv Robotics Inc. Nasdaq: Serv Develops and operates AI-powered autonomous self-driving sidewalk delivery robots. They were axed in 2021 after being acquired by delivery service Postmates Uber Technologies Inc. NYSE: UBER. Uber is not only an investor but also a partner and customer.
Serve Robotics has struck a deal with Uber Eats to deploy 2,000 autonomous AI-powered sidewalk delivery robots by 2025. Serv, Serve will not sell robots but will actually operate a fleet to make deliveries. Currently, Serve Robots only operates in Los Angeles, California, but is expected to begin delivery in Dallas, Texas. The deal with the company has also been announced Shake Shack Inc. NYSE: SHAK For delivery services. NVIDIA invested $3.7 million in the company through convertible notes in April 2024.
Developing third-generation servo robots in partnership with Wing Aviation
The third-generation robots are equipped with NVIDIA Jetson Orin modules that offer 5X more computing, Oster Inc NYSE: OUST Upgraded sensors and LidarLarger cargo compartment and smoother suspension, improved water resistance and 40% faster emergency braking. The company has also partnered with autonomous drone delivery service Wing for long-distance deliveries of over five miles. Serv robots can wing flying drones to complete deliveries five to six miles away. Because drones fly a straight line in the air, bypassing traffic, deliveries are much faster. Service robots are paid a year or in operations.
Beyond delivery, robots work inside the restaurant
Serve Robotics acquired Webu, a kitchen robotics company that made the AutoCAD robot used by Chipotle Mexican Grill Inc. NYSE: CMG To make guacamole. Chipotle produces more than 100 million pounds of guacamole annually. The acquisition brings Serve one step closer to becoming a one-stop shop for restaurant automation technology, providing restaurant automation and food delivery automation.
Full cost recovery for each robot within 12 months
Service robots are completing deliveries in Los Angeles with a 99% completion rate. The service will have 250 robots by the end of 2024 and 2,000 robots will be deployed in 2025. Full cost recovery for each robot is expected to occur within 12 months. Servo is also outsourcing the manufacturing of its robots Magna International Inc. NYSE: MGA.
CEO of Serve Robotics Dr. Ali Kashani commented, “Regarding our agreement with Uber Eats to deploy 2,000 robots by year-end 2025, we are ahead of schedule with initial manufacturing and rollout. We plan to deploy 2,000 new robots in multiple markets. Stay on track next year.”
Kashani concluded, “Additionally, we announced the potential acquisition of Weibo, which brings us into a strategically closer service offering, and we entered into partnerships with Wing Aviation and Shake Shack to expand our reach. Important The point is, we successfully raised $32.3 million in new capital. Provide financial flexibility and fund our expansion plans.”
Before considering Recursion Pharmaceuticals, you may want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified Five stocks That top analysts are quietly telling their clients to buy now before the broader market hits… and Recursion Pharmaceuticals was not on the list.
While Recursion Pharmaceuticals currently has a “hold” rating among analysts, top analysts believe these five stocks are better buys.
As the AI market heats up, investors with a vision for artificial intelligence are likely to see real returns. Learn about the industry as a whole, as well as seven companies that are harnessing the power of AI.
